我們已在上線!
進一步了解
JNCE
Jounce Therapeutics, Inc. Common Stock
JNCE
JNCE
已下市
JNCE已於2023年5月3日下市。
關於: Jounce Therapeutics Inc is a clinical stage immunotherapy company. It is engaged in developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients. The company primarily operates only in the United States. The company has developed a suite of integrated technologies that comprise a Translational Science Platform, enabling it to comprehensively interrogate the cellular and molecular composition of tumors.
員工: 141
新聞
正面
中性
負面
市場情緒
3個月
正面
0%
中性
0%
負面
0%
我們尚未收到任何關於JNCE的最新新聞文章。
價格圖表採用Lightweight Charts™實作